Robert Mittendorff II bought $20.0M of Carlsmed (CARL)
Executed Jul 24 2025, disclosed Jul 25 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Jul 24 2025), the stock returned -15.0% (delay-adjusted); from the execution session (Jul 24 2025), -15.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Robert Mittendorff II (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Carlsmed, Inc. (CARL). Across 1 priced purchase filing, the average 21-session return was -15.0% from execution and -15.0% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of CARL (1,333,333 sh × $15.00, as filed), executed Jul 24 2025.
Healthcare · Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery sol…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→